Huland E, Heinzer H, Huland H
Department of Urology, University of Hamburg, University Clinic Eppendorf, Germany.
Anticancer Res. 1999 Jul-Aug;19(4A):2679-83.
We report 6 years of experience in 116 patients who used inhaled interleukin-2 (IL-2) and were treated in different protocols with natural, recombinant glycosylated and recombinant nonglycosylated IL-2.
All protocols had in common high-dose inhalation of IL-2, either exclusively (11%), with low-dose systemic IL-2 (33%), or with low-dose systemic IL-2 and interferon-alpha (56%). Maximal toxicity per total treatment time (median treatment time, 7.2 months) was mild and at a low incidence (16%) of WHO grade 3 toxicity. Treatment was allowed in patients for whom systemic IL-2 was not suitable.
Progressive pulmonary metastases responded in 15% of patients for a median of 15.5 months (range 4.1-33) and were stabilized in 55% for a median of 6.6 months (range, 3-51.7). Overall response rate was 16%, 49%, and 35%, respectively. Median overall response duration was 9.6 mo. Median achieved survival was 11.8 months (range 1.7-68.8).
Inhaled IL-2 prevents progress of pulmonary metastases effectively in 70% of patients. Local use of IL-2 allows the use of the full potential of cytokines with little or no toxicity.
我们报告了116例使用吸入性白细胞介素-2（IL-2）的患者的6年经验，这些患者采用不同方案接受天然、重组糖基化和重组非糖基化IL-2治疗。
所有方案的共同点是高剂量吸入IL-2，单独使用（11%）、联合低剂量全身用IL-2（33%）或联合低剂量全身用IL-2和α干扰素（56%）。每总治疗时间（中位治疗时间为7.2个月）的最大毒性为轻度，世界卫生组织3级毒性的发生率较低（16%）。全身用IL-2不适用的患者也可接受治疗。
15%的患者肺部进行性转移灶有反应，中位反应时间为15.5个月（范围4.1 - 33个月），55%的患者病情稳定，中位稳定时间为6.6个月（范围3 - 51.7个月）。总体缓解率分别为16%、49%和35%。中位总体缓解持续时间为9.6个月。中位总生存期为11.8个月（范围1.7 - 68.8个月）。
吸入IL-2可有效阻止70%患者肺部转移灶的进展。局部使用IL-2可充分发挥细胞因子的潜力，且毒性很小或无毒性。
